Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cells.
Würzburg, Germany. In Immunol Res, 02 Feb 2016
Polo-like kinase 1 (PLK1) is overexpressed in many cancer types including leukemia, and clinical studies demonstrated that targeting PLK1 using selective PLK1 inhibitors resulted in inhibition of proliferation and induction of apoptosis predominantly in tumor cells, supporting the feasibility of PLK1 as target for anticancer therapy.
Erythroblast enucleation is a dynein-dependent process.
More papers using
Akita, Japan. In Exp Hematol, 24 Jan 2016
We found that EHNA, a dynein inhibitor, and monastrol, a kinesin Eg5 inhibitor, as well as various inhibitors of MTOC regulators, including ON-01910 (Plk-1), MLN8237 (aurora A), hesperadin (aurora B) and LY294002 (PI3K) all inhibited CFU-E cytokinesis.
Host-pathogen interactions: leukocyte phagocytosis and associated sequelae
In Cell Death & Disease, 2001
... anti-SR-A (clone SRA-E5, Trans Genic Inc., Kobe, Japan) and anti-LOX-1, anti-MARCO and anti-CD36 (clones 23C11, PLK1 and FA6-152, respectively, Cell Sciences, Canton, MA, USA) ...